8-K: Aptevo Therapeutics Announces Promising Remission Data in Frontline AML Trial

Aptevo Therapeutics reports that two additional patients in the RAINIER trial achieved remission within 30 days of treatment with mipletamig in combination with standard of care for frontline AML.

Summary

• Aptevo Therapeutics announced positive interim results from its RAINIER trial, a Phase 1b/2 dose optimization study evaluating mipletamig in combination with venetoclax and azacitidine for frontline acute myeloid leukemia (AML) patients unfit for intensive chemotherapy.
• Two additional patients in Cohort 2 of the RAINIER trial achieved remission within 30 days of treatment.
• Across two trials, 9 out of 10 frontline AML patients achieved remission when treated with the mipletamig combination therapy.
• The overall remission rate among frontline patients receiving the triplet combination is 90%, outperforming the 66% remission rate observed with venetoclax and azacitidine alone.
• The frontline patient triplet therapy complete remission (CR) rate of 70% outperforms the CR rate from a venetoclax + azacitidine only study of 36% (Viale-A Pivotal trial).
• No cytokine release syndrome (CRS) has been observed in the RAINIER trial to date.
• Cohort 2 includes six patients dosed at the 18mcg level, consistent with the completed dose expansion trial.
• Aptevo is also developing ALG.APV-527, a bispecific conditional 4-1BB agonist, in collaboration with Alligator Bioscience, for the treatment of multiple solid tumor types.

Sentiment

Score: 8

Explanation: The document presents highly positive clinical trial results, indicating a significant improvement in remission rates for AML patients. The absence of CRS in the RAINIER trial further enhances the positive sentiment. However, the inherent risks associated with clinical-stage biotechnology companies and forward-looking statements temper the overall optimism.

Positives

• High remission rate (90%) in frontline AML patients treated with mipletamig combination therapy.
• Complete remission rate (70%) exceeds benchmark venetoclax + azacitidine therapy (36%).
• No CRS observed in the RAINIER trial, indicating a favorable safety profile.
• Mipletamig has orphan drug designation for AML.
• ALG.APV-527 shows promising data in a Phase 1 dose escalation trial, with signs of clinical activity and good tolerability.

Negatives

• One patient in Cohort 2 experienced disease progression and passed away, although this was deemed unrelated to the study drugs.

Risks

• The forward-looking statements are subject to various risks and uncertainties, including those related to clinical trial outcomes, regulatory approvals, and market conditions.
• The trial design includes combination therapies that may make it difficult to accurately ascertain the benefits of mipletamig.
• The company's ability to secure strategic partnerships or raise funds on acceptable terms is uncertain.

Future Outlook

Aptevo anticipates continued progress in its clinical programs, including further data readouts for mipletamig and ALG.APV-527, and aims to improve treatment outcomes for cancer patients.

Management Comments

• Dirk Huebner, MD, Chief Medical Officer of Aptevo, stated that the emerging pattern supports mipletamig's impact on treatment outcomes in frontline AML patients unfit for intensive chemotherapy.
• Dirk Huebner, MD, Chief Medical Officer of Aptevo, stated that one of the primary goals with the RAINIER trial is to demonstrate the contribution of mipletamig's unique mechanism of action when used in combination with venetoclax and azacitidine.

Industry Context

The announcement highlights Aptevo's efforts to address unmet needs in AML treatment, particularly for patients who are not candidates for intensive chemotherapy. The company is positioning mipletamig as a potential improvement over the standard of care venetoclax and azacitidine doublet therapy. The company compares their results to Immunogen's Pivekimab sunirine (IMGN632) Phase Ib/II ASH 2023.

Comparison to Industry Standards

• The 90% remission rate achieved with mipletamig in combination with venetoclax and azacitidine outperforms the 66% remission rate observed with venetoclax and azacitidine alone in the Viale-A trial.
• The 70% complete remission rate with the triplet therapy exceeds the 36% rate with venetoclax and azacitidine alone in the Viale-A trial.
• Mipletamig monotherapy results are comparable to other clinical trials, such as the Pivekimab dose escalation trial.
• The company compares their results to Immunogen's Pivekimab sunirine (IMGN632) Phase Ib/II ASH 2023.

Stakeholder Impact

• Positive impact on shareholders due to promising clinical trial results.
• Potential for improved treatment outcomes for AML patients, particularly those unfit for intensive chemotherapy.
• Potential for increased value for Alligator Bioscience due to the co-development of ALG.APV-527.

Next Steps

• Continued enrollment and data collection in Cohort 2 of the RAINIER trial.
• Further clinical evaluation of mipletamig in combination with venetoclax and azacitidine.
• Continued clinical evaluation for the treatment of multiple solid tumors for ALG.APV-527.

Key Dates

Keywords

Aptevo Therapeutics, Mipletamig, AML, RAINIER trial, Bispecific, Immunotherapy, Venetoclax, Azacitidine, ALG.APV-527, Oncology